ProShare Advisors LLC Sells 11,355 Shares of LeMaitre Vascular, Inc. $LMAT

ProShare Advisors LLC decreased its stake in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 14.4% in the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 67,707 shares of the medical instruments supplier’s stock after selling 11,355 shares during the quarter. ProShare Advisors LLC’s holdings in LeMaitre Vascular were worth $5,925,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of LMAT. Royal Bank of Canada grew its position in shares of LeMaitre Vascular by 1.5% during the first quarter. Royal Bank of Canada now owns 114,176 shares of the medical instruments supplier’s stock valued at $9,579,000 after purchasing an additional 1,735 shares in the last quarter. AQR Capital Management LLC grew its holdings in LeMaitre Vascular by 36.4% during the 1st quarter. AQR Capital Management LLC now owns 27,878 shares of the medical instruments supplier’s stock valued at $2,339,000 after buying an additional 7,445 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in LeMaitre Vascular by 4.7% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,078 shares of the medical instruments supplier’s stock worth $1,013,000 after acquiring an additional 539 shares during the last quarter. Millennium Management LLC raised its holdings in shares of LeMaitre Vascular by 119.8% during the 1st quarter. Millennium Management LLC now owns 211,222 shares of the medical instruments supplier’s stock worth $17,722,000 after acquiring an additional 115,141 shares in the last quarter. Finally, Goldman Sachs Group Inc. boosted its position in shares of LeMaitre Vascular by 27.0% during the 1st quarter. Goldman Sachs Group Inc. now owns 262,445 shares of the medical instruments supplier’s stock valued at $22,019,000 after acquiring an additional 55,804 shares during the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock.

LeMaitre Vascular Price Performance

Shares of LMAT stock opened at $86.60 on Friday. The company has a debt-to-equity ratio of 0.44, a current ratio of 13.58 and a quick ratio of 11.45. The company’s 50-day simple moving average is $84.76 and its two-hundred day simple moving average is $87.82. The company has a market capitalization of $1.96 billion, a P/E ratio of 37.33, a P/E/G ratio of 1.95 and a beta of 0.72. LeMaitre Vascular, Inc. has a one year low of $71.42 and a one year high of $105.55.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on LMAT shares. Wells Fargo & Company decreased their price target on shares of LeMaitre Vascular from $97.00 to $93.00 and set an “equal weight” rating on the stock in a research note on Friday, November 7th. Wall Street Zen downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Saturday, December 6th. Cantor Fitzgerald reissued a “neutral” rating and set a $95.00 price objective on shares of LeMaitre Vascular in a research note on Monday, November 10th. Zacks Research lowered LeMaitre Vascular from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 1st. Finally, Weiss Ratings restated a “buy (b-)” rating on shares of LeMaitre Vascular in a report on Monday, December 29th. Four research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the company. According to MarketBeat.com, LeMaitre Vascular currently has a consensus rating of “Moderate Buy” and an average price target of $100.20.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.